Market Overview

UPDATE: Wedbush Securities Raises PT to $105 on HeartWare International as FDA Approves HVAD

Related HTWR
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise

Wedbush Securities reiterated its Outperform rating on HeartWare International (NASDAQ: HTWR) and increased its price target from $101 to $105.

Wedbush Securities commented, "FDA approves HVAD for Bridge-to-Transplant (BTT). The good: sintered device and non-restrictive label. The not-as-good: Label includes DT data snapshot with stroke rate imbalance. Favorable overall and maintain expectations for HVAD to take majority share of US BTT market by 2014. … We spoke with a number of US LVAD physicians at the American Heart Association (AHA) conference earlier this month and heard a unanimous opinion that the HVAD does not have a devicespecific thrombosis issue. Moreover, those with limited or no experience using the HVAD in clinical studies appear eager to test-drive the device."

HeartWare International closed at $89.54 on Tuesday.

Latest Ratings for HTWR

DateFirmActionFromTo
Aug 2014JP MorganMaintainsOverweight
May 2014OppenheimerMaintainsOutperform
Apr 2014Goldman SachsDowngradesNeutralSell

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (HTWR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters